Fatty acid (FA) profiles as potentially relevant components of Crohn's disease (CD) have been insufficiently analysed. We sought to explore the plasma profiles of n-3 and n-6 polyunsa-turated fatty acids (PUFAs) in newly diagnosed untreated active CD. We included 26 consecutive CD pediatric patients (<19 years) and 14 healthy controls (HCs). Disease characteristics, including inflammatory markers, dietary histories, and the Pediatric Crohn's Disease Activity Index (PCDAI), were obtained. The profiles of plasma FAs in plasma lipid classes were analysed by gas chromatography with FID detection of methyl esters. The erythrocyte sedimentation rate, C-reactive protein level and fecal calprotectin level (all p<0.001) were significantly higher in CD patients than in HCs. Most changes were observed in plasma phospholipids (PLs), such as a higher content of n-3 and changes in n-6 long-chain PUFAs in the CD group. The CD group had a lower ratio of n-6/n-3 PUFAs in PLs (p<0.001) and triacylglycerols (TAGs) (p<0.01). Correlations of the FA content in plasma PLs with disease activity scores of CD were also observed, which were positive for the sum of monounsaturated fatty acids (MUFAs) as well as oleic acid (18:1n-9) (both p<0.05). The metabolism of PUFAs is significantly altered even in treatment-naive newly diagnosed active pediatric CD, and the content of major FAs in PLs correlates with disease activity and inflammatory markers, thus probably contributing to the still unclear early disease pathogenesis.

Division of Pediatric Gastroenterology Department of Pediatrics Faculty Hospital Faculty of Medicine in Pilsen Charles University Prague Pilsen Czech Republic

See more in PubMed

CHILTON FH, DUTTA R, REYNOLDS LM, SERGEANT S, MATHIAS RA, SEEDS MC. Precision nutrition and omega-3 polyunsaturated fatty acids: A case for personalized supplementation approaches for the prevention and management of human diseases. Nutrients. 2017;9:1165. doi: 10.3390/nu9111165. PubMed DOI PMC

COSTEA I, MACK DR, LEMAITRE RN, ISRAEL D, MARCIL V, AHMAD A, AMRE DK. Interactions between the dietary polyunsaturated fatty acid ratio and genetic factors determine susceptibility to paediatric Crohn’s disease. Gastroenterology. 2014;146:929–931. doi: 10.1053/j.gastro.2013.12.034. PubMed DOI

DANILUK U, DANILUK J, KRASNODEBSKA M, LOTOWSKA JM, SOBANIEC-LOTOWSKA ME, LEBENSZTEJN DM. The combination of fecal calprotectin with ESR, CRP and albumin discriminates more accurately children with Crohn’s disease. Adv Med Sci. 2019;64:9–14. doi: 10.1016/j.advms.2018.08.001. PubMed DOI

DECSI T, KOLETZKO B. Fatty acid composition of plasma lipid classes in healthy subjects from birth to young adulthood. Eur J Pediatr. 1994;153:520–525. doi: 10.1007/s004310050184. PubMed DOI

ESTEVE-COMAS M, RAMÍREZ M, FERNÁNDEZ-BAÑARES F, ABAD-LACRUZ A, GIL A, CABRÉ E, GONZÁLEZ-HUIX F, MORENO J, HUMBERT P, GUILERA M. Plasma polyunsaturated fatty acid pattern in active inflammatory bowel disease. Gut. 1992;33:1365–1369. doi: 10.1136/gut.33.10.1365. PubMed DOI PMC

ESTEVE-COMAS M, NUÑEZ MC, FERNÁNDEZ-BAÑARES F, ABAD-LACRUZ A, GIL A, CABRÉ E, GONZÁLEZ-HUIX F, BERTRÁN X, GASSULL MA. Abnormal plasma polyunsaturated fatty acid pattern in non-active inflammatory bowel disease. Gut. 1993;34:1370–1373. doi: 10.1136/gut.34.10.1370. PubMed DOI PMC

FAEGAN BG, SANDBORN WJ, MITTMANN U, BAR-MEIR S, D’HAENS G, BRADETTE M, COHEN A, DALLAIRE C, PONICH TP, McDONALD JWD, HÉBUTERNE X, PARÉ P, KLVANA P, NIV Y, ARDIZZONE S, ALEXEEVA O, ROSTOM A, KIUDELIS G, SPLEISS J, GILGEN D, ET AL. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trial. JAMA. 2008;299:1690–1697. doi: 10.1001/jama.299.14.1690. PubMed DOI

FERNÁNDEZ-BAÑARES F, ESTEVE-COMAS M, MANÉ J, NAVARRO E, BERTRÁN X, CABRÉ E, BARTOLÍ R, BOIX J, PASTOR C, GASSULL MA. Changes in mucosal fatty acid profile in inflammatory bowel disease and experimental inflammation. Clin Nutr. 1997;16:177–183. doi: 10.1016/S0261-5614(97)80003-9. PubMed DOI

FOLCH J, LEES M, SLOAN-STANLEY GH. A simple method for the isolation and purification of total lipids from animal tissue. J Biol Chem. 1957;226:497–509. doi: 10.1016/S0021-9258(18)64849-5. PubMed DOI

GEERLING BJ, HOUWELINGEN AC, V, BADART-SMOOK A, STOCKBRUGEGER RW, BRUMMER RJ. The relation between antioxidant status and alterations in fatty acid profile with Crohn disease and controls. Scand J Gastroenterol. 1999;34:1108–1116. doi: 10.1080/003655299750024913. PubMed DOI

GONZÁLEZ-GIL EM, SANTABÁRBARA J, SIANI A, AHRENS W, SIOEN I, EIBEN G, GÜNTHER K, IACOVIELLO L, MOLNAR D, RISÉ P, RUSSO P, TORNARITIS M, VEIDEBAUM T, GALLI C, MORENO LA. Whole-blood fatty acids and inflammation in European children: the IDEFICS Study. Eur J Clin Nutr. 2016;70:819–823. doi: 10.1038/ejcn.2015.219. PubMed DOI

GROGAN JL, CASSON DH, TERRY A, BURDGE GC, EL-MATARY W, MARK DALZELL A. Enteral feeding therapy for newly diagnosed pediatric Crohn’s disease: a double blind randomized controlled trial with two years follow-up. Inflamm Bowel Dis. 2012;18:246–253. doi: 10.1002/ibd.21690. PubMed DOI

HARRIS C, DEMMELMAIR H, Von BERG A, LEHMANN I, FLEXEDER C, KOLETZKO B, HEINRICH J, STANDL M. Associations between fatty acids and low-grade inflammation in children from the LISAplus birth cohort study. Eur J Clin Nutr. 2017;71:1303–1311. doi: 10.1038/ejcn.2017.73. PubMed DOI

HOU JK, ABRAHAM B, EL-SERAG H. Dietary intake and risk of developing inflammatory bowel disease: A systematic review of the literature. Am J Gastroenterol. 2011;106:563–573. doi: 10.1038/ajg.2011.44. PubMed DOI

HYAMS J, MARKOWITZ J, OTLEY A, ROSH J, MACK D, BOUSVAROS A, KUGATHASAN S, PFEFFERKORN M, TOLIA V, EVANS J, TREEM W, WYLLIE R, ROTHBAUM R, Del ROSARIO J, KATZ A, MEZOFF A, OLIVA-HEMKER M, LERER T, GRIFFITHS A PEDIATRIC INFLAMMATORY BOWEL DISEASE COLLABORATIVE RESEARCH GROUP. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005;41:416–421. doi: 10.1097/01.mpg.0000183350.46795.42. PubMed DOI

INNES JK, CALDER PC. Omega-6 fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids. 2018;132:41–48. doi: 10.1016/j.plefa.2018.03.004. PubMed DOI

JACKSON KA, BYRNE NM, MAGAREY AM, HILLS AP. Minimizing random error in dietary intakes assessed by 24-h recall, in overweight and obese adults. Eur J Clin Nutr. 2008;62:537–543. doi: 10.1038/sj.ejcn.1602740. PubMed DOI

JANSSON J, WILLING B, LUCIO M, FEKETE A, DICKSVED J, HALFVARSON J, TYSK C, SCHMITT-KOPPLIN P. Metabolomics reveals metabolic biomarkers of Crohn’s disease. PLoS One. 2009;4:e6386. doi: 10.1371/journal.pone.0006386. PubMed DOI PMC

LEVINE A, KOLETZKO S, TURNER D, ESCHER JC, CUCCHIARA S, De RIDDER L, KOLHO K-L, VERES G, RUSSELL RK, PAERREGAARD A, BUDERUS S, GREER M-LC, DIAS JA, VEEREMAN-WAUTERS G, LIONETTI P, SLADEK M, De CARPI JM, STAIANO A, RUEMMELE FM, WILSON DC, ET AL. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58:795–806. doi: 10.1097/MPG.0000000000000239. PubMed DOI

LEVINE A, GRIFFITHS A, MARKOWITZ J, WILSON DC, TURNER D, RUSSELL RK, FELL J, RUEMMELE FM, WALTERS T, SHERLOCK M, DUBINSKY D, HYAMS JS. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314–1321. doi: 10.1002/ibd.21493. PubMed DOI

LEVY E, RIZWAN Y, THIBAULT L, LEPAGE G, BRUNET S, BOUTHILLIER L, SEIDMAN E. Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr. 2000;71:807–815. doi: 10.1093/ajcn/71.3.807. PubMed DOI

LEWIS JD, ABREU MT. Diet as a trigger or therapy for inflammatory bowel diseases. Gastroenterology. 2017;152:398–414. doi: 10.1053/j.gastro.2016.10.019. PubMed DOI

MARION-LETELLIER R, SAVOYE G, BECK PL, PANACCIONE R, GHOS S. Polyunsaturated fatty acids in inflammatory bowel diseases: a reappraisal of effects and therapeutic approaches. Inflamm Bowel Dis. 2013;19:650–661. doi: 10.1097/MIB.0b013e3182810122. PubMed DOI

MARTON LT, GOULART RA, CARVALHO ACA, BARBALHO SM. Omega fatty acids and inflammatory bowel diseases: An overview. Int J Mol Sci. 2019;20:4851. doi: 10.3390/ijms20194851. PubMed DOI PMC

NAGATAKE T, KUNISAWA J. Emerging roles of metabolites of ω3 and ω6 essential fatty acids in the control of intestinal inflammation. Int Immunol. 2019;31:569–577. doi: 10.1093/intimm/dxy086. PubMed DOI PMC

NIELSEN AA, JORGENSEN LGM, NIELSEN JN, EIVINDSON M, GRØNBAEK H, VIND I, HOUGAARD DM, SKOGSTRAND K, JENSEN S, MUNKHOLM P, BRANDSLUND I, HEY H. Omega-3 fatty acids inhibit an increase of proinflamatory cytokines in patients with active Crohn’ disease compared with omega-6 fatty acids. Aliment Pharmacol Ther. 2005;22:1121–1128. doi: 10.1111/j.1365-2036.2005.02698.x. PubMed DOI

PERREAULT M, ROKE K, BADAWI A, NIELSEN DE, ABDELMAGID SA, EL-SOHEMY A, MA DWL, MUTCH DM. Plasma levels of 14:0, 16:0, 16:1n−7, and 20:3n−6 are positively associated, but 18:0 and 18:2n−6 are inversely associated with markers of inflammation in young healthy adults. Lipids. 2014;49:255–263. doi: 10.1007/s11745-013-3874-3. PubMed DOI

SAIKA A, NAGATAKE T, KUNISAWA J. Host- and microbe-dependent dietary lipid metabolism in the control of allergy, inflammation, and immunity. Front Nutr. 2019;6:36. doi: 10.3389/fnut.2019.00036. PubMed DOI PMC

SCOVILLE EA, ALLAMAN MM, ADAMS DW, MOTLEY AK, PEYTON SC, FERGUSON SL, HORST SN, WILLIAMS CS, BEAULIEU DB, SCHWARTZ A, WILSON KT, COBURN LA. Serum polyunsaturated fatty acids correlate with serum cytokines and clinical disease activity in Crohn’s disease. Sci Rep. 2019;9:2882. doi: 10.1038/s41598-019-39232-z. PubMed DOI PMC

SERHAN CN. Novel pro-resolving lipid mediators in inflammation are leads for resolution physiology. Nature. 2014;510:92–101. doi: 10.1038/nature13479. PubMed DOI PMC

SERHAN CN. Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators. J Thromb Haemost. 2009;(Suppl 1):44–48. doi: 10.1111/j.1538-7836.2009.03396.x. PubMed DOI

SOCHA P, RYZKO J, KOLETZKO B, CELINSKA-CEDRO D, WOYNAROWSKI M, CZUBKOWSKI P, SOCHA J. Essential fatty acid depletion in children with inflammatory bowel disease. Scand J Gastroenterol. 2005;40:573–577. doi: 10.1080/00365520510012136. PubMed DOI

STEEL DM, RYD W, ASCHER H, STRNADVIK B. Abnormal fatty acid pattern in intestinal mucosa of children with coeliac disease is not reflected in serum phospholipids. J Pediatr Gastroenterol Nutr. 2006;43:318–323. doi: 10.1097/01.mpg.0000228107.98863.45. PubMed DOI

SÝKORA J, POMAHAČOVÁ R, KRESLOVÁ M, CVALÍNOVÁ D, ŠTYCH P, SCHWARZ J. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol. 2018;24:2741–2763. doi: 10.3748/wjg.v24.i25.2741. PubMed DOI PMC

TREBBLE TM, WOOTTON SA, MAY A, ERLEWYN-LAJEUNESSE MDS, CHAKRABORTY A, MULLEE MA, STROUD MA, BEATTIE RM. Essential fatty acid status in pediatric Crohn’s disease: relationship with disease activity and nutritional status. Aliment Pharmacol Ther. 2003;18:433–442. doi: 10.1046/j.1365-2036.2003.01707.x. PubMed DOI

USAMI M, KOMURASAKI T, HANADA A, KINOSHITA K, OHATA A. Effect of gamma-ALA or docosahexaenoic acid on tight junction permeability in intestinal monolayer cells and their mechanism by protein kinase C activation and/or eicosanoid formation. Nutrition. 2003;19:150–156. doi: 10.1016/S0899-9007(02)00927-9. PubMed DOI

VECKA M, TVRZICKÁ E, STANKOVÁ B, ŽÁK A. Effect of column and software on gas chromatographic determination of fatty acids. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;770:91–99. doi: 10.1016/S1570-0232(01)00630-4. PubMed DOI

YAQOOB P, CALDER CP. Fatty acids and immune function: new insight into mechanisms. Br J Nutr. 2007;98(Suppl 1):S41–S45. doi: 10.1017/S0007114507832995. PubMed DOI

Circulating levels of WISP-1 (Wnt1-inducible signaling pathway protein 1) and other selected adipokines in children with inflammatory bowel disease